Activity ID



November 8, 2019

Format Type


CME Credit



CME Provider

National Comprehensive Cancer Network


After decades of glacially slow progress, treatment advances are finally beginning to accelerate in the acute leukemias. This is especially true for acute myeloid leukemia (AML) where, until very recently, hematology/oncology specialists were still using the same old 7+3 cytotoxic chemotherapy regimen that became standard of care in the 1970s. Suddenly during 2017 the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010. Progress in acute lymphoblastic leukemia (ALL) also leaped forward during 2017, with FDA approval of tisagenlecleucel, the first-ever chimeric antigen receptor (CAR) T cell therapy for patients with relapsed or refractory disease. While a cure for all acute leukemias remains elusive, great progress is being made. Clinicians need to be aware that recommendations for initiating, combining, and sequencing treatments are rapidly changing, along with guidelines for avoiding or managing adverse effects. All members of the oncology care team, and their patients, need a deeper understanding of the efficacy, safety, and side effect profiles of these novel agents. This activity will improve the level of care provided by diplomates caring for patients with acute leukemia by educating them on the latest updates to the NCCN guidelines for treating this patient population.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

• Outline molecular markers used to guide clinical management of AML and ALL
• Identify emerging novel agents and targeted molecular markers in the management of relapsed or refractory AML
• Identify new provisional entities for AML and ALL based on the 2016 WHO classification update and emerging data
• Describe the standard of care for older adults with AML
• Identify targetable molecular abnormalities in the management of AML
• Outline novel and emerging treatment options in the management of AML in older adults
• Review the clinical data and discuss recent options for relapsed or refractory ALL treatment
• Summarize major adverse events that result from immunotherapy use in the management of relapsed or refractory ALL
• Identify novel agents being investigated in relapsed or refractory ALL management
• Summarize current methods used to monitor minimal residual disease in acute lymphoblastic leukemia and acute myeloid leukemia
• Outline the clinical utility of MRD assessment in ALL clinical management
• Describe the clinical utility and caveats of the methods used to monitor minimal residual disease in AML


Acute Myeloid Leukemia


Medical Knowledge, Patient Care & Procedural Skills, Systems-based Practice

CME Credit Type

AMA PRA Category 1 Credit

Practice Setting

Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.